Carlos de Sousa
Directeur Général chez ULTIMOVACS ASA
Fortune : 9 395 $ au 30/04/2024
Postes actifs de Carlos de Sousa
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ULTIMOVACS ASA | Directeur Général | 01/06/2020 | - |
| Investor Relations Contact | - | - | |
| University of Lisbon | Corporate Officer/Principal | - | - |
Ultimovacs AB
 Ultimovacs AB Pharmaceuticals: MajorHealth Technology Part of Ultimovacs ASA, Ultimovacs AB engages in pharmaceutical development. The CEO of the Swedish company is Carlos de Sousa. Ultimovacs was acquired by Ultimovacs ASA from Immuneed AB on August 29, 2018 for $6.05 million. | Directeur Général | - | - |
Historique de carrière de Carlos de Sousa
Anciens postes connus de Carlos de Sousa
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| MENDUS AB | Directeur Général | 01/10/2016 | 13/12/2019 |
| Investor Relations Contact | 01/10/2016 | 13/12/2019 | |
| President | 01/10/2016 | 13/12/2019 | |
| ECTIN RESEARCH AB | Directeur/Membre du Conseil | 01/01/2020 | - |
| Independent Dir/Board Member | 01/01/2020 | - | |
Takeda A/S
 Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Corporate Officer/Principal | - | - |
Novartis Pharma AG
 Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | - | - |
| ZEALAND PHARMA A/S | Corporate Officer/Principal | 01/12/2015 | - |
to-BBB Holding BV
 to-BBB Holding BV Pharmaceuticals: GenericHealth Technology to-BBB Holding BV operated as a holding company with interest in providing central nervous system drug technology to the pharmaceutical and biotechnology industries. The firm developed medicines for the treatment of brain diseases. The company was headquartered in The Hague, the Netherlands. | Corporate Officer/Principal | - | - |
| ░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░░░░ ░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░░ ░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - |
Formation de Carlos de Sousa
| The Leonard N Stern School of Business | Masters Business Admin |
| University of Lisbon | Doctorate Degree |
Statistiques
Internationale
| Suède | 4 |
| Pays-Bas | 3 |
| Danemark | 3 |
Opérationnelle
| Corporate Officer/Principal | 9 |
| Chief Executive Officer | 3 |
| Investor Relations Contact | 2 |
Sectorielle
| Health Technology | 11 |
| Consumer Services | 3 |
| Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| NEWRON PHARMACEUTICALS S.P.A. | Health Technology |
| ZEALAND PHARMA A/S | Health Technology |
| MENDUS AB | Health Technology |
| ULTIMOVACS ASA | Health Technology |
| ECTIN RESEARCH AB | Health Technology |
| Entreprise privées | 7 |
|---|---|
to-BBB technologies BV
 to-BBB technologies BV Pharmaceuticals: MajorHealth Technology BBB Therapeutics BV develops medicines for brain disease treatment. The firm uses its platform technology to enhance the delivery of established and marketed drugs over the blood brain-barrier. It offers its patented central nervous system (CNS) drug targeting technology to their partners in pharmaceutical and biotechnology industry. The firm's products include 2B3-101 and 2B3-201. The company was founded by Pieter Jaap Gaillard, Bert de Boer, and Alfred N. Nijkerk in 2003 and is headquartered in Leiden, the Netherlands. | Health Technology |
| Pfizer Saudi Ltd. | |
Schwartz Pharma AG
 Schwartz Pharma AG Pharmaceuticals: MajorHealth Technology Schwartz Pharma AG is a German company. | Health Technology |
to-BBB Holding BV
to-BBB Holding BV Pharmaceuticals: GenericHealth Technology to-BBB Holding BV operated as a holding company with interest in providing central nervous system drug technology to the pharmaceutical and biotechnology industries. The firm developed medicines for the treatment of brain diseases. The company was headquartered in The Hague, the Netherlands. | Health Technology |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
Takeda A/S
Takeda A/S Financial ConglomeratesFinance Takeda A/S engages in holding or owning of securities in other companies other than banks. The company was founded on January 4, 2005 and is headquartered in Taastrup, Denmark. | Finance |
Ultimovacs AB
Ultimovacs AB Pharmaceuticals: MajorHealth Technology Part of Ultimovacs ASA, Ultimovacs AB engages in pharmaceutical development. The CEO of the Swedish company is Carlos de Sousa. Ultimovacs was acquired by Ultimovacs ASA from Immuneed AB on August 29, 2018 for $6.05 million. | Health Technology |
- Bourse
- Insiders
- Carlos de Sousa
- Expérience